Recombinant Human IFNW1 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg5386
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human IFNW1 protein Leu22-Ser195 (Accession# P05000) with a rabbit IgG Fc tag at the N-terminus. |
| GeneID | 3467 |
| Accession | P05000 |
| PredictedSize | 47.0 kDa |
| SDS-PAGE | 47-60 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
IFNW1 (Interferon Omega 1) is a secreted type I interferon cytokine, belonging to the IFN-α/ω subfamily, with broad-spectrum antiviral, antitumor, and immunomodulatory activities. IFNW1 binds to the type I interferon receptor (IFNAR1/IFNAR2 heterodimer), activates the JAK-STAT signaling pathway, induces the expression of interferon-stimulated genes (ISGs), inhibits viral replication, enhances NK cell activity, and promotes antigen presentation. Compared with other type I interferons, IFNW1 exhibits higher antiviral potency and lower cytotoxicity, holding potential application value in the treatment of chronic viral infections (such as hepatitis B and HIV).
References:
1. Cheng, Hong et al. Neurogenetics vol. 25,4 (2024): 337-350. 2. Mørup, Sara Bohnstedt et al. AIDS research and therapy vol. 21,1 27. 3 May. 2024.